Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Lines Up $1 Billion For China R&D

This article was originally published in The Pink Sheet Daily

Executive Summary

In-country research staff will increase over six-fold to approximately 1,000.

You may also be interested in...

China's Universities and Pharma: A Change In Power Balance?

China's pharma companies may one day soon find themselves without the R&D support of the country's leading universities, and companies have the country's push to improve IP protection to thank

Novartis Signs MOU To Invest $100 Million In R&D, Exchanges With Korean Scientists By 2013

SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences

Novartis To Step Up Investment In China

SHANGHAI - Swiss drug maker Novartis plans to deepen its investment in China this year despite the West's economic downturn, and will expand its research and development center here while launching new drugs in the Chinese market, according to high-level Novartis executives

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts